(Q37819278)

23 August 2017

1 reference

title

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review (English)

1 reference

23 August 2017

1 reference

1 reference

adenoid cystic carcinoma

1 reference

Scott A Laurie

1

1 reference

23 August 2017

Alan L Ho

2

1 reference

23 August 2017

Matthew G Fury

3

1 reference

23 August 2017

Eric Sherman

4

1 reference

23 August 2017

David G Pfister

5

1 reference

23 August 2017

10 December 2010

1 reference

Lancet Oncology Commission

23 August 2017

1 reference

23 August 2017

12

1 reference

23 August 2017

815-824

1 reference

23 August 2017

8

1 reference

Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Prognostic factors in minor salivary gland cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Stage means more than grade in adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Distant metastasis in adenoid cystic carcinoma of salivary origin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Chemotherapy for salivary gland cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Chemotherapy for adenocystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Chemotherapy of malignant major salivary gland neoplasms.A 25-year review of M.D. Anderson hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Intra-arterial cisplatin treatment of adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin therapy for adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Chemotherapy of advanced salivary gland neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Preliminary experience with chemotherapy in advanced salivary gland neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Content and quality of currently published phase II cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

HER2 expression in salivary gland carcinomas: dependence on histological subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970245-X

7 January 2021

10.1016/S1470-2045(10)70245-X

Identifiers

DOI

1 reference

23 August 2017

1 reference